Edward van der Horst
Directeur Technique/Scientifique/R&D chez SENSEI BIOTHERAPEUTICS, INC.
Fortune : 35 445 $ au 30/04/2024
Postes actifs de Edward van der Horst
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 07/12/2022 | - |
| Corporate Officer/Principal | 01/09/2019 | 07/12/2022 |
Historique de carrière de Edward van der Horst
Anciens postes connus de Edward van der Horst
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Zenith Epigenetics Ltd.
 Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Corporate Officer/Principal | 01/07/2017 | 01/08/2019 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01/10/2010 | 01/01/2017 |
Formation de Edward van der Horst
| Ludwig-Maximilians-Universität München | Graduate Degree |
| Max Planck Institute of Biochemistry | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Allemagne | 3 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Zenith Epigenetics Ltd. operates as a Canadian clinical-stage biotechnology company. The private company is based in Calgary, Canada. | Commercial Services |
- Bourse
- Insiders
- Edward van der Horst
- Expérience
